[144] Elanco Animal Health Incorporated SEC Filing
Elanco Animal Health (ELAN) reported a proposed sale of 49,333 shares of common stock through UBS on the NYSE with an aggregate market value of $830,000, representing approximately 0.01% of the 496,646,504 shares outstanding. The filing lists the acquisition history: 1,536 shares on 12/03/2020, 16,738 shares on 02/22/2021, and 31,059 shares on 02/22/2022, all identified as stock awards.
The notice indicates no securities sold in the past three months and includes the signatory's representation that they do not know any material nonpublic information about the issuer. The form references Rule 144 procedures and mentions Rule 10b5-1 plan disclosure but does not provide a plan adoption or instruction date.
Elanco Animal Health (ELAN) ha segnalato la proposta di vendita di 49,333 azioni ordinarie tramite UBS sul NYSE, per un valore di mercato aggregato di $830,000, pari a circa il 0.01% delle 496,646,504 azioni in circolazione. Il deposito riporta la cronologia delle acquisizioni: 1,536 azioni il 12/03/2020, 16,738 azioni il 02/22/2021 e 31,059 azioni il 02/22/2022, tutte indicate come stock awards.
L'avviso indica che non sono stati venduti titoli negli ultimi tre mesi e contiene la dichiarazione del firmatario di non essere a conoscenza di informazioni materiali non pubbliche sull'emittente. Il modulo fa riferimento alle procedure della Rule 144 e menziona la disclosure relativa a un piano ai sensi della Rule 10b5-1, ma non riporta la data di adozione o di istruzione del piano.
Elanco Animal Health (ELAN) informó una propuesta de venta de 49,333 acciones ordinarias a través de UBS en la NYSE, con un valor de mercado agregado de $830,000, que representa aproximadamente el 0.01% de las 496,646,504 acciones en circulación. La presentación detalla el historial de adquisición: 1,536 acciones el 12/03/2020, 16,738 acciones el 02/22/2021 y 31,059 acciones el 02/22/2022, todas identificadas como stock awards.
El aviso indica que no se han vendido valores en los últimos tres meses e incluye la declaración del firmante de no conocer información material no pública sobre el emisor. El formulario hace referencia a los procedimientos de la Rule 144 y menciona la divulgación de un plan según la Rule 10b5-1, pero no proporciona la fecha de adopción ni de instrucción del plan.
Elanco Animal Health (ELAN)은 NYSE에서 UBS를 통해 49,333주 보통주를 매도할 예정이라고 보고했으며, 총 시가가 $830,000으로 발행주식 496,646,504주의 약 0.01%에 해당합니다. 신고서에는 취득 내역이 기재되어 있습니다: 12/03/2020에 1,536주, 02/22/2021에 16,738주, 02/22/2022에 31,059주로, 모두 주식 보상(stock awards)으로 확인됩니다.
통지서에는 최근 3개월 동안 매도한 증권이 없다고 명시되어 있으며, 서명인은 발행회사에 관해 중대한 미공개 정보를 알지 못한다는 진술을 포함하고 있습니다. 양식은 Rule 144 절차를 언급하고 Rule 10b5-1 계획 공시를 적시하지만, 계획의 채택일이나 지시일은 기재되어 있지 않습니다.
Elanco Animal Health (ELAN) a déclaré une proposition de vente de 49,333 actions ordinaires via UBS sur le NYSE, pour une valeur de marché totale de $830,000, représentant environ 0.01% des 496,646,504 actions en circulation. Le dossier énumère l'historique des acquisitions : 1,536 actions le 12/03/2020, 16,738 actions le 02/22/2021 et 31,059 actions le 02/22/2022, toutes identifiées comme des stock awards.
L'avis indique que aucun titre n'a été vendu au cours des trois derniers mois et contient la déclaration du signataire selon laquelle il ne connaît aucune information matérielle non publique concernant l'émetteur. Le formulaire renvoie aux procédures de la Rule 144 et mentionne la divulgation d'un plan Rule 10b5-1, mais ne fournit pas de date d'adoption ni d'instruction du plan.
Elanco Animal Health (ELAN) meldete einen geplanten Verkauf von 49,333 Stammaktien über UBS an der NYSE mit einem Gesamtmarktwert von $830,000, was etwa 0.01% der 496,646,504 ausstehenden Aktien entspricht. Die Einreichung listet die Erwerbshistorie auf: 1,536 Aktien am 12/03/2020, 16,738 Aktien am 02/22/2021 und 31,059 Aktien am 02/22/2022, jeweils als Stock Awards ausgewiesen.
Die Mitteilung gibt an, dass in den letzten drei Monaten keine Wertpapiere verkauft wurden, und enthält die Erklärung des Unterzeichners, dass ihm keine wesentlichen nichtöffentlichen Informationen über den Emittenten bekannt sind. Das Formular verweist auf die Verfahren nach Rule 144 und erwähnt die Offenlegung eines Rule-10b5-1-Plans, nennt jedoch kein Datum für die Annahme oder Weisung des Plans.
- Sale details fully disclosed: 49,333 shares with aggregate market value of $830,000, broker identified as UBS, and approximate sale date provided (08/11/2025).
- Acquisition history provided: All shares were acquired as stock awards on 12/03/2020, 02/22/2021, and 02/22/2022, totaling the 49,333 shares reported.
- No Rule 10b5-1 plan date: The filing references trading plans but does not state a plan adoption or instruction date for the sale.
- Limited context on intent: The form does not explain whether the sale is part of a preplanned disposition or for personal/liquidity reasons.
Insights
TL;DR Routine insider sale notice: 49,333 shares (~0.01% of outstanding) via UBS; acquisitions were stock awards from 2020–2022.
The Form 144 discloses a proposed sale of 49,333 Elanco common shares with an aggregate market value of $830,000 to be executed through UBS on the NYSE. The filing is specific about acquisition dates and quantities and reports no sales in the prior three months, which supports transparency. Given the size—about 0.01% of outstanding shares—the transaction appears immaterial to company capitalization based on information provided.
TL;DR Disclosure is complete on holdings and broker, but the filing omits any Rule 10b5-1 plan adoption date.
The filer documents the source of the shares (stock awards) and the broker executing the sale (UBS), and affirms lack of material nonpublic information. However, the filing does not state whether a Rule 10b5-1 trading plan exists or provide an adoption date or instruction date, which would clarify whether the sale is pre-planned. The absence of recent sales in the prior three months is explicitly reported.
Elanco Animal Health (ELAN) ha segnalato la proposta di vendita di 49,333 azioni ordinarie tramite UBS sul NYSE, per un valore di mercato aggregato di $830,000, pari a circa il 0.01% delle 496,646,504 azioni in circolazione. Il deposito riporta la cronologia delle acquisizioni: 1,536 azioni il 12/03/2020, 16,738 azioni il 02/22/2021 e 31,059 azioni il 02/22/2022, tutte indicate come stock awards.
L'avviso indica che non sono stati venduti titoli negli ultimi tre mesi e contiene la dichiarazione del firmatario di non essere a conoscenza di informazioni materiali non pubbliche sull'emittente. Il modulo fa riferimento alle procedure della Rule 144 e menziona la disclosure relativa a un piano ai sensi della Rule 10b5-1, ma non riporta la data di adozione o di istruzione del piano.
Elanco Animal Health (ELAN) informó una propuesta de venta de 49,333 acciones ordinarias a través de UBS en la NYSE, con un valor de mercado agregado de $830,000, que representa aproximadamente el 0.01% de las 496,646,504 acciones en circulación. La presentación detalla el historial de adquisición: 1,536 acciones el 12/03/2020, 16,738 acciones el 02/22/2021 y 31,059 acciones el 02/22/2022, todas identificadas como stock awards.
El aviso indica que no se han vendido valores en los últimos tres meses e incluye la declaración del firmante de no conocer información material no pública sobre el emisor. El formulario hace referencia a los procedimientos de la Rule 144 y menciona la divulgación de un plan según la Rule 10b5-1, pero no proporciona la fecha de adopción ni de instrucción del plan.
Elanco Animal Health (ELAN)은 NYSE에서 UBS를 통해 49,333주 보통주를 매도할 예정이라고 보고했으며, 총 시가가 $830,000으로 발행주식 496,646,504주의 약 0.01%에 해당합니다. 신고서에는 취득 내역이 기재되어 있습니다: 12/03/2020에 1,536주, 02/22/2021에 16,738주, 02/22/2022에 31,059주로, 모두 주식 보상(stock awards)으로 확인됩니다.
통지서에는 최근 3개월 동안 매도한 증권이 없다고 명시되어 있으며, 서명인은 발행회사에 관해 중대한 미공개 정보를 알지 못한다는 진술을 포함하고 있습니다. 양식은 Rule 144 절차를 언급하고 Rule 10b5-1 계획 공시를 적시하지만, 계획의 채택일이나 지시일은 기재되어 있지 않습니다.
Elanco Animal Health (ELAN) a déclaré une proposition de vente de 49,333 actions ordinaires via UBS sur le NYSE, pour une valeur de marché totale de $830,000, représentant environ 0.01% des 496,646,504 actions en circulation. Le dossier énumère l'historique des acquisitions : 1,536 actions le 12/03/2020, 16,738 actions le 02/22/2021 et 31,059 actions le 02/22/2022, toutes identifiées comme des stock awards.
L'avis indique que aucun titre n'a été vendu au cours des trois derniers mois et contient la déclaration du signataire selon laquelle il ne connaît aucune information matérielle non publique concernant l'émetteur. Le formulaire renvoie aux procédures de la Rule 144 et mentionne la divulgation d'un plan Rule 10b5-1, mais ne fournit pas de date d'adoption ni d'instruction du plan.
Elanco Animal Health (ELAN) meldete einen geplanten Verkauf von 49,333 Stammaktien über UBS an der NYSE mit einem Gesamtmarktwert von $830,000, was etwa 0.01% der 496,646,504 ausstehenden Aktien entspricht. Die Einreichung listet die Erwerbshistorie auf: 1,536 Aktien am 12/03/2020, 16,738 Aktien am 02/22/2021 und 31,059 Aktien am 02/22/2022, jeweils als Stock Awards ausgewiesen.
Die Mitteilung gibt an, dass in den letzten drei Monaten keine Wertpapiere verkauft wurden, und enthält die Erklärung des Unterzeichners, dass ihm keine wesentlichen nichtöffentlichen Informationen über den Emittenten bekannt sind. Das Formular verweist auf die Verfahren nach Rule 144 und erwähnt die Offenlegung eines Rule-10b5-1-Plans, nennt jedoch kein Datum für die Annahme oder Weisung des Plans.
FAQ
What does the Elanco (ELAN) Form 144 disclose about the proposed sale?
When and how were the shares being sold acquired?
Did the filer report any sales of Elanco securities in the past three months?
What representation did the seller make about material nonpublic information?
What class of security and exchange are involved in this filing?
